GlassScriptPhysician profile
Terese A Wenzel
NPI 1710559794
$3,477.47
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $1,573 · 2023: $1,245 · 2024: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.36 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $433.39 | 2022-2024 | Spravato, Invega Sustenna |
| Novo Nordisk INC | $260.58 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $230.69 | 2021-2024 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $178.14 | 2023 | Auvelity |
| Lilly USA, LLC | $171.34 | 2022-2024 | Reyvow, Amyvid, Emgality |
| Acadia Pharmaceuticals INC | $167.72 | 2022-2023 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $161.84 | 2022 | |
| Tris Pharma INC | $152.03 | 2023 | Dyanavel Xr, Quillivant, Quillichew Er |
| Lundbeck LLC | $144.51 | 2022-2023 | Rexulti |
| Grt US Holding, INC. | $139.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $115.85 | 2022-2023 | |
| Pfizer INC. | $96.86 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $77.96 | 2022-2024 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $47.20 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.72 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.60 | 2022-2023 | Trintellix |
| Alkermes, INC. | $41.81 | 2023 | Aristada, Vivitrol, Lybalvi |
| Mdd US Operations, LLC | $39.55 | 2022-2023 | Xadago, Apokyn, Myobloc |
| Corium, LLC | $38.55 | 2023 | Adlarity, Azstarys |
| Sunovion Pharmaceuticals INC. | $35.91 | 2022 | |
| Neos Therapeutics, LP | $32.22 | 2022-2024 | Adzenys Xr-Odt |
| Ucb, INC. | $25.74 | 2023 | Briviact |
| Impel Pharmaceuticals INC. | $25.26 | 2022 | |
| Avanir Pharmaceuticals, INC. | $23.97 | 2022 | |
| Sumitomo Pharma America, INC. | $23.23 | 2023 | Aptiom |
| Alexion Pharmaceuticals, INC. | $22.66 | 2022 | |
| Genzyme Corporation | $22.34 | 2021 | |
| Amneal Pharmaceuticals LLC | $20.74 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.39 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.83 | 2023 | Quviviq |
| Amgen INC. | $18.68 | 2021 | |
| Currax Pharmaceuticals LLC | $16.09 | 2022 | |
| Acorda Therapeutics, INC | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terese Wenzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.